Odonate Therapeutics, Inc.
ODTC
$22,005.00
Updated: 23/09/2026, 07:43:07
Market Cap
$8.05B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
US
Stock valuation chart
One-year closing share-price history for ODTC
Company Profile
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
USD
OTC
CEO: Kevin C. Tang
Employees: 137
Asset Summaries
Latest generated summaries for ODTC
No summaries found.
Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for ODTC.
- Share price
- $22,005.00
- Market cap
- $8.05B
- Exchange
- OTC
- Currency
- USD
- CEO
- Kevin C. Tang
- Employees
- 137
- IPO date
- 07/12/2017
- Beta
- 0.423
- Last dividend
- $0.00
- Day range
- $22,005.00 – $22,005.00
- 52-week range
- $22,005.00 – $358,000.00
- 1-day performance
- 29.44%
- 1-year performance
- 0.00%
- Current drawdown (1Y)
- -93.85%
- CIK
- 0001717452
- CUSIP
- 676079403
- ISIN
- US6760794031
- Created
- 07/12/2025, 05:34:41
- Last update
- 23/09/2026, 07:43:07
Track Odonate Therapeutics, Inc. with an AI analyst
See which prediction-market events move ODTC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Latest Database News
News linked to ODTC from your Railway `news_articles` table.
No news found for this symbol.